Sustaining momentum into the second half — execution on 20% guidance
Strong Q1 sets up Q2 expectations: Apollo Hospitals is on track for 20% hospital revenue growth, with analyst consensus bullish on margin control and new-unit ramp. Street sees 15% upside; the quarter will test execution.
The number that matters
For Apollo Hospitals in Q2, the critical metric is consolidated revenue — whether the company sustains the 21% growth momentum from Q1 and maintains trajectory toward its 20% full-year hospital revenue guidance. The second read is EBITDA margin: can Apollo hold margins near 15.5% while absorbing the drag from new hospitals (₹140–150 Cr EBITDA loss guided for all of FY27)? This is the execution test the Street is watching.
What to expect
~₹7,400–7,500 Cr
20% growth on-track; Q1 was ₹7,043.5 Cr (+21% YoY). Sequential Q1→Q2 seasonality typical.
~₹1,120–1,180 Cr
On-plan ~15% margin. New hospitals ramp expected to drag, but core margin stable.
~₹600–640 Cr
Consensus EPS ₹34 vs ₹26.3 YoY. Q1 showed 38% PAT growth to ₹610 Cr; guidance unchanged.
A strong Q2 would see consolidated revenue grow 19–21% YoY (maintaining Q1 momentum), EBITDA margin hold above 15%, and PAT growth above 30% YoY. This would confirm management's 20% FY27 hospital revenue guidance is intact and new-hospital drag is manageable. A weak Q2 would show revenue growth below 18%, margin compression below 14.5%, or PAT growth deceleration below 20% — signaling either execution challenges in organic hospitals or faster-than-expected new-hospital losses.
On track?
Yes. Q1 FY27 significantly beat Street expectations (consolidated PAT at ₹610 Cr vs consensus ₹553 Cr; revenue ₹7,043.5 Cr +21% YoY). Management's 20% hospital revenue growth guidance for FY27 — comprising 13–14% organic growth from existing hospitals and ~7% from new units over 24 months — remains the baseline. The company guided for ₹140–150 Cr EBITDA loss from new hospitals in FY27, unchanged from prior guidance. Q2 is the halfway checkpoint: Street expects consistent execution, not material surprises.
What the Street says
Since last quarter
Aug 25, 2026
Routine: adoption of audited FY26 financials, dividend approval, appointment of auditors — no operational surprises.
45th AGM held
Aug 28, 2026
FY 2025–26 annual report submitted; details strategic initiatives and business portfolio. No new guidance.
Updated Annual Report filed
Oct 12, 2026
Board scheduled for Nov 4, 2026 to consider and approve Q2 FY27 (unaudited) results. Standard reporting cycle.
Board meeting intimation
Oct 16, 2026
Notification to BSE/NSE with enclosed annexure. Content not disclosed; routine exchange filing.
Regulatory filing
Operative summary: No material corporate actions, pledges, or insider activity flagged since Q1. Ownership: FII fell 112 bps QoQ to 41.50% (from 42.62%), DII gained 96 bps to 23.72%. Promoter stake stable at 28.02%. The slide in FII is modest; the pickup in DII offsets. No red flags on capital structure or leverage.
What to watch on result day
1 · Revenue growth rate
The Street expects Q2 consolidated revenue to grow 19–21% YoY (in line with Q1's 21%). Any slip below 18% would suggest organic growth deceleration or new-hospital headwinds emerging faster than guided. Watch the standalone (domestic) vs. consolidated split and mix from new units.
2 · EBITDA margin and PAT leverage
Q1 delivered 15.5% EBITDA margin despite new-hospital ramp. The Street is betting margins hold 14.8–15.3% in Q2. If margins fall below 14.5% or PAT growth decelerates below 25%, it signals new-hospital drag is steeper or cost pressures are higher — requiring guidance cuts. PAT leverage (growth multiple vs. revenue growth) is the arbiter of execution quality.
3 · Full-year guidance tone
Management will likely reiterate 20% hospital revenue growth and ₹140–150 Cr new-hospital EBITDA loss for FY27. Any guidance tweaks — up or down — will ripple. Watch for commentary on new-unit occupancy ramp, discharge volumes in core hospitals, and pricing momentum. If tone is cautious, stock may gap down despite a beat.
Apollo Hospitals has set up Q2 as a continuity test: after an exceptional Q1 (21% revenue growth, 38% PAT growth, margin expansion), the Street expects the company to sustain momentum while executing on 20% full-year hospital revenue guidance and managing new-hospital losses. Analyst consensus is firmly bullish (26 BUY, 3 HOLD, 1 SELL) with an 18% median upside to ₹9,985. The stock is near its 200-day SMA and trading at a slight discount to ATH (₹9,069), leaving room for re-rating on a beat. The key risks are margin compression from new hospitals ramping faster than guided and organic growth deceleration in the core business. On Nov 4, watch the revenue growth rate, EBITDA margin hold, and PAT leverage — these will confirm whether the trajectory is intact.
Informational and educational content only. Not investment advice.